Given the brain-penetrating ability of LDHA inhibitor stiripentol and isosafrole42, we developed preclinical trials evaluating the anti-tumor effect of pharmacological inhibition of LDHA in glioblastoma mouse models. This evidence concerns the gene LDHA and neoplasm.